- Conditions
- Newborn Morbidity
- Interventions
- Resuscitation Personnel
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 11,257
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Iron Overload, Excessive Body Iron Burden
- Interventions
- R2*-UTE, R2*-GRE, Liver biopsy
- Device · Procedure
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Tourette Syndrome
- Interventions
- d-cycloserine, Placebo pill, Behavior Therapy
- Drug · Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hemophilia A
- Interventions
- New FVIII products
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 27
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 23 more
- Conditions
- Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy
- Interventions
- Not listed
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Seattle, Washington
- Conditions
- Polycystic Kidney Disease, Adult, ADPKD
- Interventions
- Lixivaptan
- Drug
- Lead sponsor
- Palladio Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more
- Conditions
- Hypercholesterolemia, Familial
- Interventions
- ISIS 301012
- Drug
- Lead sponsor
- Kastle Therapeutics, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more
- Conditions
- Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis
- Interventions
- BX004-A, Placebo
- Drug
- Lead sponsor
- BiomX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 15 more
- Conditions
- Dysferlinopathy, LGMD2B Now Classified as LGMDR2, Miyoshi Myopathy
- Interventions
- Not listed
- Lead sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
- Other
- Eligibility
- 10 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 6
- States / cities
- Orange, California • Palo Alto, California • St Louis, Missouri + 3 more
- Conditions
- Niemann-Pick Disease, Type C
- Interventions
- IB1001
- Drug
- Lead sponsor
- IntraBio Inc
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Gastroesophageal Reflux, Apnea, Bradycardia
- Interventions
- Erythromycin, Multi-channel intra-luminal impedance (MII) pH monitoring, Placebo (D5W)
- Drug · Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 14 Days and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
- Interventions
- Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 7 Days to 30 Days
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Heart Defect, Congenital
- Interventions
- Xeltis Bioabsorbable Pulmonary Valved Conduit
- Device
- Lead sponsor
- Xeltis
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Hollywood, Florida + 4 more
- Conditions
- Tourette Syndrome
- Interventions
- TEV-50717, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 33
- States / cities
- Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more
- Conditions
- Abetalipoproteinemia
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
- Interventions
- DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
- Genetic · Other
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Congenital Adrenal Hyperplasia, Healthy
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 9 Years to 40 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Physical Disability
- Interventions
- EnhanceWellness for Disability (EW-D), Wellness Education
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 45 Years to 64 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Joint Bleed, Hemophilia A
- Interventions
- handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform
- Device
- Lead sponsor
- Washington Institute for Coagulation
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Waldenström Macroglobulinemia
- Interventions
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Duarte, California • Stanford, California + 5 more
- Conditions
- Migraine Disease, Patent Foramen Ovale
- Interventions
- Prasugrel 5mg, Transcatheter Closure of Patent Foramen Ovale
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B, Recurrent Thyroid Gland Medullary Carcinoma, Sporadic Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
- Interventions
- Sorafenib Tosylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2022
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Durham, North Carolina • Columbus, Ohio
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma (PN)
- Interventions
- Selumetinib, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more